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This study aimed to evaluate well-documented diagnostic antigens, named B13, 1F8 and JL7 recombinant proteins, 
as potential markers of seroconversion in treated chagasic patients. Prospective study, involving 203 patients treated 
with benznidazole, was conducted from endemic areas of northern Argentina. Follow-up was possible in 107 out of 
them and blood samples were taken for serology and PCR assays before and 2, 3, 6, 12, 24 and 36 months after treat-
ment initiation. Reactivity against Trypanosoma cruzi lysate and recombinant antigens was measured by ELISA. The 
rate of decrease of antibody titers showed nonlinear kinetics with an abrupt drop within the first three months after 
initiation of treatment for all studied antigens, followed by a plateau displaying a low decay until the end of follow-up. 
At this point, anti-B13, anti-1F8 and anti-JL7 titers were relatively close to the cut-off line, while anti-T. cruzi antibodies 
still remained positive. At baseline, 60.8% (45/74) of analysed patients tested positive for parasite DNA by PCR and dur-
ing the follow-up period in 34 out of 45 positive samples (75.5%) could not be detected T. cruzi DNA. Our results suggest 
that these antigens might be useful as early markers for monitoring antiparasitic treatment in chronic Chagas disease.
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Chagas disease or American trypanosomiasis, 
caused by the parasite Trypanosoma cruzi, is endemic in 
much of the Americas, from the southern United States 
to Argentina and Chile. It is the fourth most common 
tropical disease, after malaria, tuberculosis and schisto-
somiasis, currently affecting 7-6 million people (WHO 
2015). The risk of infection with T. cruzi is directly relat-
ed to poverty, but due to migrations, several cases have 
been reported throughout the world (Lescure et al. 2008, 
Muñoz et al. 2009, Jackson et al. 2010).
In Argentina, it is estimated as many as 1.5 million 
patients have Chagas disease and 2.2 million people in 
risk of T. cruzi infection (WHO 2015). The endemic area 
covers the north of the country where the conditions, 
such as high levels of poverty and social exclusion, low 
population density, mostly rural, subsistence economy, 
and a weak health system, favor not only T. cruzi infec-
tion but also for the development of this disease.
Once the individual acquires the parasite, the infec-
tion starts with an acute phase, followed by a chronic stage 
which includes asymptomatic and symptomatic cases, 
with cardiac, digestive manifestations or mixed patterns 
(WHO 2015). Up to now, the available treatment is based 
on two drugs: nifurtimox and benznidazole (BNZ). Che-
motherapy against T. cruzi infection is strongly recom-
mended for all cases during the acute stage, in children 
under 15 years old and reactivated infections in immuno-
compromised patients (Bianchi et al. 2015), but its effec-
tiveness during the chronic stages is still under revision 
(Cançado 2002, Viotti et al. 2006, 2014). Some studies 
suggest that BNZ for asymptomatic or early symptomatic 
cases may improve parasite clearance rates (de Andrade 
et al. 1996, Sosa-Estani et al. 1998). In 1999, a panel of 
experts reached the consensus that patients with chronic 
Chagas disease should be treated with an anti-T. cruzi 
medication (PAHO 1999). From this recommendation, 
many studies are being conducted. Thus, results from a 
multicenter, placebo-controlled trial involving BNZ for 
the treatment of Chagas cardiomyopathy showed that 
the drug significantly diminished serum parasite detec-
tion, but did not improve cardiac clinical manifestation 
(Morillo et al. 2015). In parallel, another trial with long-
term follow-up in adult patients, is being conducted in 
Argentina to evaluate whether BNZ treatment change the 
evolution of chronic Chagas disease (Riarte 2013). Other 
randomised clinical studies, with shorter follow-up peri-
ods, based on the safety and efficacy of new drugs such 
as posaconazole, studied this drug alone or in combina-
tion with BNZ (Molina et al. 2014, and STOP CHAGAS 
clinical trial, Identifier: NCT01377480).
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After treatment, the criterion of cure in chronic Cha-
gas disease is the persistence of negative parasitological 
and serological results (Porrás et al. 2015). Unfortunate-
ly, T. cruzi lysate antibody seroconversion occurs sev-
eral years after antiparasitic therapy in most individuals, 
while parasitological methods are consistently nega-
tive (Guedes et al. 2011, Machado-de-Assis et al. 2012). 
Thus, the identification of early markers of seronegative 
conversion is an important and imperative step to evalu-
ate Chagas disease treatment.
The aim of this study was to evaluate if well-known se-
rological markers could have an early predictive value and 
be useful to monitor drug therapy response, by measuring 
antibody (Ab) levels over time in a cohort of patients with 
chronic Chagas disease treated with BNZ. For this purpose, 
we selected the recombinant proteins named B13, 1F8 and 
JL7, because they are recognised by most chronic chagasic 
patients and are currently used in commercial kits for diag-
nosis (Umezawa et al. 1999, 2003, Ponce et al. 2005).
SUBJECTS, MATERIALS AND METHODS
Patients and study design - Prospective study was car-
ried out from years 2000-2004 in Añatuya, a city located 
in a highly Chagas disease-endemic area in the Prov-
ince of Santiago del Estero - Argentina. Three hundred 
and twelve T. cruzi-infected adults volunteers aged 15-55 
years were recruited and 270 patients in the asymptomatic 
or cardiac chronic phase of Chagas disease were eligible.
Inclusion criteria were positive diagnostic for Chagas 
disease by commercial ELISA and indirect hemagglutina-
tion assays, according to Argentina’s National Guidelines 
and the World Health Organization (WHO) recommen-
dations. Exclusion criteria included the visceral damage, 
presence of systemic arterial hypertension, liver or kid-
ney failure, severe cardiac lesions associated with other 
cardiac diseases, pregnancy, lactation, alcoholism and 
hypersensitivity to the drug. BNZ was given three times 
daily over 60 days at a total dose 5 mg/kg/day (100 mg/
tablet: Radanil, Roche). During treatment, patients were 
subjected to clinical examination to evaluate side effects.
Blood samples were collected at the following in-
stances: T0, before treatment; T1, two months; T2, three 
months; T3, six months; T4, one year; T5, two years and 
T6, three years after treatment onset, respectively.
The research protocol followed the tenets of the 
Declaration of Helsinki and was approved by the Local 
Medical Ethics Committees named Comité Institucional 
de Ética de Investigación en Salud - Ministerio de Salud 
y Desarrollo Social de Santiago del Estero and Comité 
de Ética del Hospital Zonal de Añatuya Monseñor Got-
tau. Before and during the beginning of this study, the 
area was under triatominae vector surveillance by offi-
cial government sanitary agents and Mundo Sano Pri-
vate Foundation (i.e., they undertook regular insecticidal 
actions against infestations). All enrolled adult patients 
gave written informed consent and the parent or guardian 
of the child participants provided informed consent on 
their behalf after the nature of the study was explained.
DNA extraction and amplification - Blood samples 
were mixed with an equal volume of 6 M guanidine 
HCl/0.2 M EDTA buffer pH: 8.0. Guanidine-EDTA blood 
(GEB) was heated for 15 min in boiling water and total 
DNA was purified from 500 µL GEB with phenol-chlo-
roform-isoamyl alcohol (25:24:1, V/V) as previously re-
ported (Schijman et al. 2003). The 330-bp variable regions 
of the T. cruzi kinetoplastid minicircle genome was am-
plified with 121 [5′-AAATAATGTACGG G(T/G)GAGA-
TGCATGA-3′] and 122 (5′-GGTTCGATTGGGGTTG-
GTGTAATATA-3′) primers by conventional PCR as 
previously described (Schijman et al. 2003).
Parasite lysate and recombinant proteins - Parasite 
extracts were obtained from T. cruzi epimastigotes CL-
Brener strain DTU Tc VI (Zingales et al. 2009), as previ-
ously described (Gómez et al. 2001).
B13, 1F8 and JL7 were expressed as GST fusion pro-
teins and purified by affinity chromatography on glutathi-
one-agarose beads as previously described (Umezawa et 
al. 1999). Protein contents were quantified by Bradford re-
agent, and all antigens were maintained at -80ºC until used.
Enzyme-linked immunosorbent assay (ELISA) - In-
house ELISAs were carried out as described previously 
(Longhi et al. 2012). Briefly, microwells (Costar Inc., 
Corning, NY) were coated overnight at 4ºC with T. cruzi 
lysate (20 μg/mL) or B13, 1F8 and JL7 recombinant pro-
teins (5 μg/mL) in 50 μL of 0.05 M carbonate-bicarbon-
ate buffer (pH 9.6). The plates were washed thrice with 
washing buffer (PBS containing 0.1% Tween-20; PBS-T) 
and then blocked with PBS-T plus 5% non-fat dry milk 
for 1 h at 37ºC. Sera diluted 1:200 in PBS-T with 1% 
non-fat dry milk were incubated in duplicate for 2 h at 
37ºC. To avoid test variability, serum samples (from T0-
T6) from a given patient were assayed on the same plate 
and sera from eight healthy individuals were also loaded 
on each plate to determine cut-off value.
After the plates were washed three times, 50 μL of al-
kaline phosphatase (for T. cruzi lysate) or peroxidase (for 
recombinant proteins) conjugated anti-human polyvalent 
immunoglobulins diluted 1:3000 in PBS-T containing 
1% non-fat dry milk, was dispensed into each well and 
incubated 1 h at 37ºC. The reaction was developed with 
p-nitrophenyl phosphate (for alkaline phosphatase) or 3, 
3’, 5, 5’ - tetramethylbenzidine substrate (for peroxidase) 
and read at 415 nm or 450 nm, respectively.
In parallel, some serum samples were also analysed 
by commercial Chagatest ELISA recombinant v4.0 
(Wiener Laboratory, Rosario, Argentina) according to 
manufacturer’s instruction.
Statistical analysis - Chi-square test for the analysis 
of drug side-effects were performed. Longitudinal panel 
data analysis was used to assess the change in Ab levels 
over time. Longitudinal data was analysed using gener-
alised linear mixed effects modelling, as implemented 
in R software 2.10.0 version (R Core Team 2013), with 
random effects specified at the level of the individual. 
Normal distribution of dependent variables was evaluated 
with Shapiro-Wilks test. Variables not normally distribut-
ed were log-transformed before analysis and log-normali-
ty confirmed with Shapiro-Wilks test for the transformed 
variables. Estimation of 95% confidence intervals (95% 
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CI) for generalised linear mixed effects regressions was 
done by Markov Chain Monte Carlo, as implemented in 
WinBUGS and R (R Core Team 2013). Statistical signifi-
cance was assumed at p < 0.05 or 95% CI.
RESULTS AND DISCUSSION
Several recombinant antigens are used for diagnosis 
of Chagas disease (Afranchino et al. 1989, dos Santos et 
al. 1992, Krieger et al. 1992, Umezawa et al. 1999, 2003, 
Di Noia et al. 2002, Camussone et al. 2009, De Marchi 
et al. 2011), but none of them has been tested as early 
markers of cure after anti-parasitic treatment. With this 
idea in mind, we decided to determine the level of anti-
bodies against three antigens, namely B13, 1F8 and JL7, 
in a cohort of patients treated with BNZ by an in-house 
ELISA method. These antigens correspond to repeat 
tandem proteins of T. cruzi and have been well described 
in other works as immunodominant antigen in Chagas 
disease (Umezawa et al. 1999, 2003, Longhi et al. 2012).
Flowchart of enrollment, treatment and follow-up is 
schematised in Fig. 1. Sixty seven out of 270 enrolled 
patients (24.8%) interrupted treatment, because of death 
(2/67, 2.9%), pregnancy (4/67, 5.9%), fail to correctly fol-
low medical prescription or adverse effects (24/67, 35.8%) 
and voluntary abandonment (37/67, 55.2%). Although 203 
completed drug therapy, only three or more follow-up 
samples could be obtained in 107 treated patients, espe-
cially due to difficulties of patients to attend to hospital 
during three years of drug monitoring. The number of 
samples analysed from T0-T6 is shown in Table. It is im-
portant to mention that the group of patients analysed was 
representative of the total cohort that completed treatment 
with similar rates of females/males and rural/urban resi-
dents (Fig. 1). Moreover, mean age of patients who com-
pleted treatment (34.5 years, N = 203) or follow-up (35.7 
years, N = 107) was also comparable, with a higher pro-
portion of patients ranged in age from 25-44 years (65%; 
132/203 and 68%; 73/107, respectively).
As it has been previously reported (Viotti et al. 2009, 
Pinazo et al. 2010) typical side effects, generally mild 
and transient, were observed in 67 out of 203 patients 
who complete treatment. The most common side effect 
proved cutaneous hypersensitivity (29/203, 14.3%) such 
as pruritus, allergy and exanthema, followed by diges-
tive disorders (18/203, 8.8%) as epigastric pain, dyspep-
sia and heartburn. In addition, 11 out of 203 patients 
(5.4%) presented headache, nauseas or vomiting, while 
nine patients suffered arthralgia and myalgia (4.4%). 
The appearance of more than one side effect was only 
observed in 12 out of 203 patients (5.9%). The incidence 
of adverse reactions was not statistically associated to 
age, sex, or place of residence -urban or rural areas- 
(Chi-square test, p = 0.43, p = 0.26, p = 0.96, respec-
tively). It is important to highlight that a high number 
of patients, who developed cutaneous hypersensitivity, 
worked in brick factories exposed to heat and sunlight.
Parasitological experiments were performed in 74 
out of 107 patients. At baseline, 60.8% (45/74) had posi-
Fig. 1: flow diagram of patient enrollment, treatment and follow-up.
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aTime in months from treatment onset; bNumber of serum samples.
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tive results for T. cruzi PCR, whereas during monitoring 
period, consistently negative PCR results were docu-
mented in 34/45 (75.5%). Similar data have been report-
ed by Morillo et al. (2015) in BENEFIT trial, showing 
that T. cruzi DNA was not detected in 73% of Argentin-
ian and Bolivian patients at the end of follow-up. How-
ever, CHAGASAZOL trial reported that 94% of patients 
treated with BNZ tested negative by PCR (Molina et al. 
2014). These differences could be related to the risk of 
exposure to the parasite, because patients included in 
CHAGASAZOL trial have been living in Barcelona, 
Spain - a non-endemic area - during the whole study. 
On the contrary, although the area was under triatomi-
nae vector surveillance, the study population in BEN-
EFIT trial and in our work belonged to endemic regions, 
where there is a real risk of exposure to reinfections, due 
to population movement to areas without vector control.
After analysing serologic response against T. cruzi 
lysate or recombinant proteins by linear mixed effects 
modelling, we observed an apparent biphasic curve for all 
antigens, with an initial rapid decline within the first three 
months followed by a plateau with a slight decay for the 
remaining 36 months of follow-up (Fig. 2). The decrease 
in Ab titers against T. cruzi lysate over time was -0.0075 
optical density (OD)/month (95% CI -0.0060 to -0.0090]), 
with a significant effect of time for each patient (Supple-
mentary figure). Similar results were obtained for Ab an-
ti-B13, anti-1F8 and anti-JL7 levels with a slope of -0.0032 
OD/month for B13 (95% CI [-0.0010 to-0.0074], -0.0041 
OD/month for 1F8 (95% CI [-0.0001 to -0.0083]) and 
-0.0032 OD/month for JL7 (95% CI [-0.0009 to -0.0075]), 
with significant effect for each patient as a function of 
time (Supplementary figure). A statistically significant 
faster rate of decline was observed for Ab titers against 
T. cruzi lysate in comparison to anti-B13, anti-1F8 and 
anti-JL7 (p < 0.01 for all comparisons, linear mixed ef-
fects model analysis). Indeed, results showed that the OD 
mean values for recombinant proteins declined progres-
sively close to the cut-off values at the end of the follow-
up, while those for T. cruzi lysate remained positive (Fig. 
2). This observation could be explained by the fact that 
sera reactivity at T0 is higher to T. cruzi lysate than with 
recombinant proteins. This data is in accordance with 
results presented by others, who observed a low rate of 
seronegative conversion of anti-T. cruzi response detected 
by conventional serological test (Sosa-Estani et al. 1998, 
2009, Viotti et al. 2011, Machado-de-Assis et al. 2013).
It is important to highlight that most sera presented 
reactivity against T. cruzi lysate and the recombinant 
proteins, as for example the Patient #115 (Fig. 3), but 
some patients did not developed detectable Ab against 
all the recombinant antigens. As shown in Fig. 3, serum 
from Patient #207 did not react with the three studied 
recombinant antigens and along with serum from Patient 
#7 were the only two samples that showed low reactivity 
against B13. Likewise five patients had a similar pattern 
response as Patient #131, seven patients as Patient #85 
and 12 patients as Patient #27 without reactivity to 1F8 
and/or JL7 (Fig. 3). In this cohort of patients, the percent-
age of reactivity against B13, 1F8 and JL7 was 98, 89 and 
82, respectively. Based on these finding, we suggest that 
no single recombinant protein would be useful for the 
assessment of therapeutic response in all patients, and 
reactivity against the three antigens should be tested in-
dividually for future treatment evaluation.
In parallel for comparison purpose, sera reactivity was 
determined by a commercial Chagatest ELISA recombi-
nant. As shown in Fig. 3, a similar pattern response to T. 
cruzi lysate was obtained, with a slight decrease in Ab 
levels, but without showing a seroconversion at end of 
follow-up, while as mentioned above, anti-B13, anti-1F8 
and anti-JL7 Ab declined progressively close to the cut-
off values at the end of follow-up. Finally, we observed 
along to monitoring that Patients #115, #131, #7, #85 and 
#27 showed decay in Ab response, especially against to 
recombinant antigens (Fig. 3) and also tested negative for 
T. cruzi DNA by PCR. On the contrary, Patient #207, who 
had no changes in reactivity against T. cruzi lysate (Fig. 
3), PCR assays remained positive during the follow-up.
Throughout the years, there have been major ad-
vances in the control of T. cruzi transmission due to vec-
tor control by insecticide spraying, but little has been 
achieved in terms of treatment of infected people. The 
fact that most of those infected individuals are from the 
poorer strata of society diminishes the interest in the de-
velopment of new drugs by the pharmaceutical compa-
nies, but it is one of the priorities for WHO in the control 
of Chagas disease. Therefore, therapy efficacy or drug 
success necessarily requires validate an accurate method 
to evaluate the course of the disease (Pinazo et al. 2014).
As mentioned above, positive prognosis after anti-
parasite treatment often is made by serological and/or 
parasitological subsequent examinations with consis-
tently negative results in time (Porrás et al. 2015). Non-
Fig. 2: antibody levels. ELISA plates were coated with Trypanosoma cru-
zi lysate, or B13, 1F8 and JL7 recombinant proteins in buffer carbonate. 
Serum samples were diluted 1/200 and tested in duplicate. Results are 
expressed as optical density (OD) means for each antigen ± standard error 
of the means (SEM). Cut-off values for T. cruzi, B13, 1F8 and JL7 recom-
binant proteins, were 0.276, 0.110, 0.367 and 0.150, respectively.
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Fig. 3: variation in optical density (OD) by the ELISA as a function of time. Results from six patients, representing typical pattern response against Tryp-
anosoma cruzi lysate, B13, 1F8 and JL7 recombinant proteins, are schematised. Chagatest ELISA recombinant v4.0 results were included in comparison 
of in-house ELISAs. Cut-off values for T. cruzi, Chagatest, B13, 1F8 and JL7 recombinant proteins, were 0.276, 0.126, 0.110, 0.367 and 0.150, respectively.
conventional serological methods, including a multiplex 
format or ELISA with recombinant proteins, have been 
developed to provide fast, easy to measure, responses to 
etiological treatments (Cooley et al. 2008, Fernández-
Villegas et al. 2011, Fabbro et al. 2013). However, there 
are no consensuses about which is the gold standard of 
post-treatment evaluation protocols to establish cure in a 
reasonably short time (Urbina 2015).
Overall, our results showed that none of the patients 
showed a seronegative conversion for anti-T. cruzi re-
sponse during the follow-up, but a significant decay in 
the Ab titer against recombinant antigens was observed 
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in the majority of the patients with chronic Chagas dis-
ease three years after the end of specific drug treatment.
Since, the level of Ab against recombinant proteins 
B13, 1F8 and JL7 decreased to cut-off line earlier than 
Ab against T. cruzi lysate and these reduction were not 
statistically associated to age, sex, or place of residence, 
results suggest that these antigens would be good candi-
dates as early markers of serological response to evaluate 
drug success. Although the main limitations of our study 
were the non-randomised design, and absence of a pla-
cebo control group due to bioethics considerations of the 
Local Medical Ethics Committee, our findings encourage 
further evaluation of these recombinant antigens in ran-
domised and controlled trial with trypanocidal drugs.
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